SCHEMBL4417409

SCHEMBL4417409

Cc1nsc2nc(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.46
CSNK1D P48730 3/20 0.44
CSNK1A1 P48729 2/20 0.44
CSNK1E P49674 1/20 0.44
MAPK10 P53779 2/20 0.42
MAPK9 P45984 2/20 0.41
SRC P12931 1/20 0.41
BRAF P15056 1/20 0.41
KDR P35968 1/20 0.41
GSK3B P49841 2/20 0.40
MAPK13 O15264 2/20 0.40
GCGR P47871 2/20 0.40
MAPK12 P53778 2/20 0.40
MAPK11 Q15759 2/20 0.40
EGFR P00533 1/20 0.40
RAF1 P04049 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
ADORA1 P30542 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4408440 0.89 MAPK14 (0.46) MAPK14CSNK1DCSNK1A1CSNK1EMAPK10
SCHEMBL4411198 0.75 MAPK14 (0.51) MAPK14CSNK1DCSNK1A1CSNK1EMAPK10
SCHEMBL2931965 0.74 MAPK14 (0.47) MAPK14CSNK1DCSNK1A1CSNK1EMAPK10
SCHEMBL2931973 0.73 MAPK14 (0.53) MAPK14CSNK1DCSNK1A1CSNK1ESRC
SCHEMBL2932183 0.70 MAPK14 (0.53) MAPK14CSNK1DCSNK1A1CSNK1ESRC
SCHEMBL4406497 0.68 MAPK14 (0.51) MAPK14CSNK1DCSNK1A1CSNK1EMAPK10
SCHEMBL1554749 0.67 MAPK14 (0.56) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL6934304 0.67 MAPK14 (0.55) MAPK14CSNK1DCSNK1A1CSNK1EMAPK10
SCHEMBL2926530 0.67 MAPK14 (0.52) MAPK14CSNK1DCSNK1A1CSNK1EMAPK10
SCHEMBL27523724 0.67 NPC1 (0.47) MAPK14CSNK1DCSNK1A1CSNK1EMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US claimed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US claimed
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US disclosed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885CSNK1D 172/4885CSNK1A1 73/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885CSNK1D 172/4885CSNK1A1 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.